Fecal Incontinence. Sphincter Augmentation. Alaiyan Bilal MD Hadassah mt scopus
|
|
- Alyson Lynn Casey
- 5 years ago
- Views:
Transcription
1 Fecal Incontinence Sphincter Augmentation Alaiyan Bilal MD Hadassah mt scopus
2 AUGMENTATION METHODS Injectables( Bulking agents) Radiofrequency
3 INJECTABLES Biomaterials Polytef, Autologous fat, GAX (glutaraldehyde cross-linked) collagen, PTQ implantstm, Durasphere, Coaptite, Zuidex is dextranomer hyaluronic acid copolymer
4 The ideal agent biocompatible, non-migratory, non-allergenic, nonimmunogenic, non-carcinogenic, easy to inject and produce durable results.
5 INJECTABLES The first report of the use of injectable bulking agents was in 1993 by Shafik - Polytetrafluroethylene (Teflon or Polytef) 11 patients with improvement in all Shafik 14 autologous fat, good shortterm results In 1998 Kumar et al.8 used glutaraldehyde cross-linked collagen 17 pts 11 short term improvement.
6 INJECTABLES Bioplastique, the equivalent of the silicone-based urological product Macroplastique 10 pts 6 months effect. carbon-coated zirconium oxide beads (Durasphere 18 pts partial short term results self-detaching cross-linked silicone microballoons with a biocompatible filler material
7 Mechanism of action augments the natural anal cushions encourages a better seal of the anal canal lumen at rest increases the length of the anal high pressure zone improvement in anal canal symmetry
8 ACYST or DURASPHERE FI Microscopic picture of pyrolitic carbon beads Each carbon bead is µm Suspension of carbon bead in a gel consisting of water and beta-d glucan.
9 Methods of injection Submucosal intersphincteric trans-sphincteric
10 Systematic Review: Route of Injection Increase complications with intersphincteric vs transphincteric and pereanal injection n=969
11 Lack of well-conducted, randomised, controlled trials from which the efficacy of anal bulking agents can be determined.
12 Dextranomer in stabilised hyaluronic acid Randomised, sham-controlled trial Patients from 8 US and 5 European centers Patients randomly assigned to receive (2:1) either anal injection of NASHA Dx (active treatment) or sham treatment After 1 month, all patients with a CCFIS of 10 or more (and no persistent adverse effects) were offered a repeat procedure Graf at al. Lancet 2011
13 Dextranomer in stabilised hyaluronic acid Randomised, sham-controlled trial 206/278 were randomly assigned to receive either active or sham treatment A 50% or greater reduction in the number of incontinence episodes: 71 (52%) patients in the active treatment group 22 (31%) patients in the sham treatment group Odds ratio 2.36, 95% CI , p=0.009). Graf at al. Lancet 2011
14 Dextranomer in stabilised hyaluronic acid Randomised, sham-controlled trial Improved QOL Graf at al. Lancet 2011
15 long-term efficacy and safety of NASHA/Dx, assessed 24 months after treatment. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence F. La Torre* and F. de la Portilla *Department of Colorectal and Pelvic Surgery, 1st College of Medicine SAPIENZA, Rome University, Rome, Italy and Coloproctology Unit, Department of General Surgery, Hospital Universitario Virgen del Rocıo, Seville, Spain Received 11 July 2012; accepted 15 December 2012; Accepted Article online 1 February 2013 ª 2013 The Authors Colorectal Disease ª 2013 The Association of Coloproctology of Great Britain and Ireland. 15,
16
17
18 Results 62.7% - responders 50% reduction in FI episodes. The median number of FI episodes declined by 68.8% (P < 0.001). incontinence free days increased from 14.6 to 21.7 at 24 months (P < 0.001). quality of life scores also showed significant improvements.
19 Conclusion NASHA/Dx is safe, effective and durable over a 24-month period
20 Long-term evaluation of bulking agents for the treatment of fecal incontinence: clinical outcomes and ultrasound evidence F. Guerra M. La Torre G. Giuliani D. Coletta S. Amore Bonapasta F. Velluti F. La Torre Tech Coloproctol (2015) 19:23 27
21 Methods median follow-up of 7 years, 19 patients with idiopathic fecal incontinence who had received bulking agent implants were evaluated. BA - Durasphere, PTQ and Solesta subcut. were used. Clinical, manometric and ultrasound assessments were carried out.
22
23 methods Median follow-up of 7 years 19 patients with idiopathic fecal incontinence who had received bulking agent implants were evaluated. Clinical, manometric and ultrasound assessments were carried out.
24 Conclusions In the long term, perianally injected bulking agents seem to lose effectiveness.. The ultrasound assessment suggests that the process of resorption is almost complete, and the implants are no longer effective in treating incontinence.
25 Author Results of Injectables N Shafik et al. 14 Material used Autologous Fat Follow -up (month s) Wexner Incontinence score Before After 24 85% improved Shafik et al. 11 PTFE 24 63% improved Malouf et al. 10 Bioplastique 6 30% improved Tjandra et al. 82 Silicone 12 50% improved Tjandra et al. 20 PTQ Sorensen et al. 33 Silicone Weiss et al. 10 ACYST
26 Results of Injectables Davis et al. 18 Dursphere Chan et al. 7 PTQ Stojkovic et al. 73 Contigen De la Portilla et al. 20 PTQ Maeda et al. 10 Bulkamid Permacol Schwander et al. 21 Hyarulonic
27 Systematic Review of Perianal implants Agent No. of studi es Morbid ity (%) n=103 0 Short term success n=458 Long term success n=564 % n % n PTQ Durasphere NASHA TM Permacol Bulkamid TM Coaptite Hussain et al BJS 2011 Fat
28 Conclusions: bulking agents Simple Ambulatory Mild - Moderate to severe incontinence Good short term outcome Minimal complications
29 Radiofrequency (SECCA TM ) Temperature-controlled radiofrequency delivery
30 Radiofrequency (SECCA TM )
31 Radiofrequency (SECCA TM )
32 Results of Radiofrequency Author (year) n F/U (months) Wexner Score Before After QOL Takahashi Efron Takahashi Felt-Bersma * 15* Takahashi Lefebure ** Kim Walega Improved Ruiz Herman Abbas Only 22% improved -- * Vaizey score ** only depression improved
33 Results: Complications Adverse Event n % Mucosal Ulcerations 2 4 % Bleeding Requiring Intervention 12 % Minor Bleeding 5 10 % Antibiotic Induced Diarrhea 7 14 % Fever 2 4 % Vomiting 1 2 % Constipation 1 2 % Groin swelling 1 2 % Hot flashes 1 2 % Efron et al, DCR 2003
34 Secca - Conclusions Ambulatory Simple Relatively safe Variable results
MEDICAL POLICY SUBJECT: BULKING AGENTS FOR TREATMENT OF URINARY OR FECAL INCONTINENCE. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BULKING AGENTS FOR (ARCHIVED DATE: 05/28/09-, EDITED DATE: 05/27/10, 05/19/11, 05/24/12, 05/23/13) PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific
More informationInjectable Bulking Agents for the Treatment of Fecal Incontinence. Policy Specific Section: September 27, 2013 January 1, 2015
Medical Policy Injectable Bulking Agents for the Treatment of Fecal Incontinence Type: Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date: September 27,
More informationSubject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
09-A9000-03 Original Effective Date: 02/15/12 Reviewed: 12/06/18 Revised: 12/15/18 Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence THIS MEDICAL COVERAGE GUIDELINE
More informationINJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
FECAL INCONTINENCE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationMedical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence EFFECTIVE DATE:02 5 2013 POLICY LAST UPDATED: 12 18 2018 OVERVIEW Bulking agents are injectable substances
More informationA Case of Fecal Incontinence: Medical and Interventional Treatment Options
A Case of Fecal Incontinence: Medical and Interventional Treatment Options HPI JP is a 69 year-old F with a 12-month history of FI. Her symptoms began after a colonoscopy She has been experiencing passive
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2014 Origination: 2/1994 Next Review: 6/2015 Policy Blue Cross and Blue Shield of Kansas
More informationProtocol. Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal (70119) Medical Benefit Effective Date: 07/01/15 Next Review Date: 05/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11,
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Last Review Status/Date: September 2015 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances that used to increase tissue bulk. They can be injected periurethrally
More informationCorporate Medical Policy
Corporate Medical Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal File Name: Origination: Last CAP Review: Next CAP Review: Last Review: injectable_bulking_agents_for_the_treatment_of_urinary_and_fecal_incontinence
More informationName of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy #: 455 Latest Review Date: July 2014 Category: Surgery Policy Grade: B Background/Definitions: As a
More informationClose. Number: Policy. Last Review 07/14/2016 Effective: 04/30/2002 Next Review: 07/13/2017. Review History
1 of 55 Close Number: 0611 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Last Review 07/14/2016 Effective: 04/30/2002 Next Review: 07/13/2017 I. Aetna considers the following
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
7.01.19 Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Section 7.0 Surgery Subsection Effective Date February 27, 2015 Original Policy Date February 27, 2015 Next Review
More informationClinical Policy: Fecal Incontinence Treatments Reference Number: PA.CP.MP.137
Clinical Policy: Fecal Incontinence Treatments Reference Number: PA.CP.MP.137 Effective Date: 01/18 Last Review Date: 12/16 Coding Implications Revision Log Description Fecal incontinence defined as the
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Last Review Status/Date: March 2017 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2017 Origination: 2/1994 Next Review: 6/2018 Policy Blue Cross and Blue Shield of Kansas
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Bulking Agents for the Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Injectable Bulking Agents for the Treatment of Urinary and
More informationMedical Policy Title: Periurethral Bulking ARBenefits Approval: <Date>
Medical Policy Title: Periurethral Bulking ARBenefits Approval: Agents for the Treatment of Incontinence Effective Date: 01/01/2012 Document: ARB0279 Revision Date: Code(s): 51715 Endoscopic injection
More informationInjectable Silicone Biomaterial (PTQ TM ) to Treat Fecal Incontinence After Hemorrhoidectomy
Original Contributions Injectable Silicone Biomaterial (PTQ TM ) to Treat Fecal Incontinence After Hemorrhoidectomy Miranda K. Y. Chan, M.B.B.S., F.R.A.C.S., Joe J. Tjandra, M.D., F.R.A.C.S. Department
More informationDuc M. Vo, MD, FACS Northwest Surgical Specialists
Duc M. Vo, MD, FACS Northwest Surgical Specialists Disclosures none Outline Definition Etiologies Exam findings Additional testing Medical management Surgical options What is fecal incontinence? Recurrent
More informationMP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Surgery End Date: 08/19/2018 Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment
More informationUrinary Incontinence. Biopolymer GmbH & Co.KG - Germany
Urinary Incontinence Treatment Options: 1. Physical Therapy: a conservative early stage treatment for UI, including pelvic floor muscles training known as Kegel exercise. 2. Medications: by means of pharmaceutical
More information2/5/2016. ABS Complications. Anal Slings-investigational
ABS Complications Anal Slings-investigational Similar to transvaginal tape or transobturator tape for UI Dacron, mersilene, polyester, and teflon mesh, fascia lata Wound infections, sinus tract, t ulcer
More informationPeriurethral Bulking Agents for the Treatment of Urinary Incontinence. Original Policy Date
MP 7.01.14 Periurethral Bulking Agents for the Treatment of Urinary Incontinence Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationMP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment of Urinary and
More informationFecal Incontinence: Beyond Conservative Therapy Presentation #1
Presentation #1 The following is a transcript from a web-based CME-certified multi-media activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational
More informationInitial Results of a New Bulking Agent for Fecal Incontinence: A Multicenter Study
ORIGINAL CONTRIBUTION Initial Results of a New Bulking Agent for Fecal Incontinence: A Multicenter Study Guillermo Rosato, M.D. 1 Pablo Piccinini, M.D. 2 Lucia Oliveira, M.D., Ph.D. 3 Angelita Habr-Gamma,
More informationORIGINAL ARTICLE. S. J. van der Hagen & W. van der Meer & P. B. Soeters & C. G. Baeten & W. G. van Gemert
Int J Colorectal Dis (2012) 27:1191 1198 DOI 10.1007/s00384-012-1468-9 ORIGINAL ARTICLE A prospective non-randomized two-centre study of patients with passive faecal incontinence after birth trauma and
More informationClinical Policy: Fecal Incontinence Treatments Reference Number: CP.MP.137 Last Review Date: 12/17
Clinical Policy: Reference Number: CP.MP.137 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Fecal
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Injectable Bulking Agents for Urinary Conditions and Fecal Incontinence Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information...
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence
More informationTransanal Radiofrequency Treatment of Fecal Incontinence
2.01.58 Transanal Radiofrequency Treatment of Fecal Incontinence Section 2.0 Medicine Effective Date January 30, 2015 Subsection Original Policy Date July 6, 2012 Next Review Date January 2016 Description
More information6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence
6 Page Male Incontinence Booklet /9/ :44 Page The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page Stress Urinary Incontinence - A Stressful Prospect
More informationDescription. Section: Medicine Effective Date: April 15, 2016 Subsection: Medicine Original Policy Date: June 7, Page: 1 of 6.
Section: Medicine Effective Date: April 15, 2016 Page: 1 of 6 Last Review Status/Date: March 2016 Description Radiofrequency (RF) energy has been investigated as a minimally invasive treatment of fecal
More informationClinical Policy Title: Injectable bulking agents for fecal incontinence
Clinical Policy Title: Injectable bulking agents for fecal incontinence Clinical policy number: 08.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date: June
More informationClinical Policy Title: Injectable bulking agents fecal incontinence
Clinical Policy Title: Injectable bulking agents fecal incontinence Clinical policy number: 08.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date: June 5, 2018
More informationPelvic Floor Disorders. Amir Darakhshan MD FRCS (Gen Surg) Consultant Colorectal and General Surgeon
Pelvic Floor Disorders Amir Darakhshan MD FRCS (Gen Surg) Consultant Colorectal and General Surgeon What is Pelvic Floor Disorder Surgical perspective symptoms of RED, FI or prolapse on the background
More informationAnnals of Long-Term Care
SUPPLEMENT TO Annals of Long-Term Care PRODUCT BULLETIN This material was prepared by HMP Communications, LLC in collaboration with Salix Pharmaceuticals. DECEMBER 2012 OVERVIEW OF FECAL INCONTINENCE Fecal
More informationTransanal Radiofrequency Treatment of Fecal Incontinence
Medical Policy Manual Surgery, Policy No. 129 Transanal Radiofrequency Treatment of Fecal Incontinence Next Review: December 2018 Last Review: December 2017 Effective: February 1, 2018 IMPORTANT REMINDER
More information2/5/2016. Evolving Surgical Treatment Approaches for Fecal Incontinence in Women: An Evidence and Cased-Based Approach
Evolving Surgical Treatment Approaches for Fecal Incontinence in Women: An Evidence and Cased-Based Approach Holly E Richter, PhD, MD, FACOG, FACS J Marion Sims Professor Obstetrics and Gynecology Professor
More informationDescription. Section: Medicine Effective Date: April 15, 2017 Subsection: Medicine Original Policy Date: June 7, Page: 1 of 6.
Page: 1 of 6 Last Review Status/Date: March 2017 Description Radiofrequency energy has been investigated as a minimally invasive treatment of fecal incontinence, in a procedure referred to as the Secca
More informationValidity of the 50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence
Citation: (2015) 6, e70; doi:10.1038/ctg.2014.20 & 2015 the American College of Gastroenterology All rights reserved 2155-384X/15 www.nature.com/ctg Validity of the 50% Response Threshold in Treatment
More informationTitle: Zuidex versus Contigen for Stress Urinary Incontinence. Date: May 30, 2007
Title: Zuidex versus Contigen for Stress Urinary Incontinence Date: May 30, 2007 Context and policy issues: Stress urinary incontinence (SUI) is the involuntary leakage of urine during exercise or movements
More informationThere are many treatment options for fecal incontinence
ORIGINAL CONTRIBUTION Does the Radiofrequency Procedure for Fecal Incontinence Improve Quality of Life and Incontinence at 1-Year Follow-Up? Dan Ruiz, M.D. 1 Rodrigo A. Pinto, M.D. 1 Tracy L. Hull, M.D.
More informationFECAL INCONTINENCE. John H. Winston, III, M.D., M.B.A.
FECAL INCONTINENCE John H. Winston, III, M.D., M.B.A. Diplomate, American Board of Colon & Rectal Surgery Diplomate, American Board of Surgery www.colorectalsurgeryservices.com Fecal Incontinence (FI)
More informationFecal incontinence (FI), defined as the involuntary loss of. Current and Emerging Treatment Options for Fecal Incontinence CLINICAL REVIEW
CLINICAL REVIEW Current and Emerging Treatment Options for Fecal Incontinence Satish S.C. Rao, MD, PhD, FRCP Abstract: Fecal incontinence (FI) is a multifactorial disorder that imposes considerable social
More informationW17: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October :00-18:00
W7: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October 204 4:00-8:00 Start End Topic Speakers 4:00 4:05 Introduction Sherif Mourad 4:05 4:20 Pathophysiology
More informationComparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents
Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents Abstract Andrew J. Steward Department of Aerospace and Mechanical Engineering University of Notre Dame, Notre Dame, IN
More informationThe technology described in this briefing is Permacol, a collagen paste that is injected into anal fistulae.
pat hways Permacol for treating anal fistulae Medtech innovation briefing Published: 23 May 2017 nice.org.uk/guidance/mib105 Summary The technology described in this briefing is Permacol, a collagen paste
More informationAnorectal Malformations
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1065 Anorectal Malformations Long-term outcome and aspects of secondary treatment JOHAN DANIELSON ACTA UNIVERSITATIS
More informationAn effective and minimally invasive bridge between conservative therapy and invasive surgery for BCD (bowel control disorder).
An effective and minimally invasive bridge between conservative therapy and invasive surgery for BCD (bowel control disorder). Mederi Therapeutics has developed this kit to help you raise awareness of
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of collagen paste for closing an anal fistula An anal fistula is a narrow tunnel
More informationA prospective multicentre study to investigate percutaneous tibial nerve stimulation for the treatment of faecal incontinence
Original article doi:1.1111/j.1463-1318.29.22.x A prospective multicentre study to investigate percutaneous tibial nerve stimulation for the treatment of faecal incontinence B. Govaert, D. Pares, S. Delgado-Aros,
More informationCurrent management of fecal incontinence: Choosing amongst treatment options to optimize outcomes
Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v19.i48.9216 World J Gastroenterol 2013 December 28; 19(48): 9216-9230 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationCorporate Medical Policy
Corporate Medical Policy Vesicoureteral Reflux, Treatment with Periureteral Bulking Agents File Name: Origination: Last CAP Review: Next CAP Review: Last Review: vesicoureteral_reflux_treatment_with_periureteral_bulking_agents
More informationReceived May 25, 2008; Revised January 21, 2009; Accepted May 17, 2009; Published June 12, 2009
Review Special Issue: Update on Lower Urinary Tract Symptoms TheScientificWorldJOURNAL (2009) 9, 466 478 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.53 Minimally Invasive Therapies for Female Stress
More informationIdentifying predictors of success of the LIFT procedure in the treatment of fistula-in-ano: does location matter?
Identifying predictors of success of the LIFT procedure in the treatment of fistula-in-ano: does location matter? Department of Colorectal Surgery Cleveland Clinic Florida Sami Chadi MD, Daniel Bekele
More informationImplantation of SphinKeeper TM : a new artificial anal sphincter
Tech Coloproctol (2016) 20:59 66 DOI 10.1007/s10151-015-1396-0 SHORT COMMUNICATION Implantation of SphinKeeper TM : a new artificial anal sphincter C. Ratto 1 L. Donisi 1 F. Litta 1 P. Campennì 1 A. Parello
More informationWider Patient Eligibility for Fecal Management Systems
1 Wider Patient Eligibility for Fecal Management Systems BACKGROUND Balloon cuff based catheters limits management of patients with poor anal sphinter tone, as it puts them at high risk for device expulsion.
More informationRECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE
RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE SAAD JUMA, MD INCONTINENCE RESEARCH INSTITUTE ENCINITAS, CA AUA STRESS URINARY INCONTINENCE GUIDELINE UPDATE INDEX PATIENTS The otherwise healthy
More informationThere is no ideal tissue or substance to be injected in
Braz J Otorhinolaryngol. 2009;75(6):801-5. ORIGINAL ARTICLE Domingos Hiroshi Tsuji 1, Flavio Akira Sakae 2, Rui Imamura 3, Luis Fernando Ferraz 4, Luiz Ubirajara Sennes 5 Use of pyrolytic carbon coated
More informationFaecal Incontinence: Assessment and Management
Mrs PK; 56 yrs; Married; 2 children Faecal Incontinence: Assessment and Management Professor Marc A Gladman MBBS DFFP PhD MRCOG FRCS (UK) FRACS Professor of Colorectal Surgery >10 years of incontinence
More informationPost- prostatectomy Incontinence - PPI
Post- prostatectomy Incontinence - PPI Dr. Kolombo Ivan, MD, FEBU Assoc.Prof. Popken Gralf MD, PhD, Assoc.Prof. Otčenášek Michal MD, PhD, Dr. Klézl Petr MD, MBA, Dr. Kolombová Jitka MD, MBA, Assoc.Prof.
More information, may spread caudally to present as a perianal abscess, laterally across the external sphincter to form an ischiorectal abscess or, rarely,
ANORECTAL ABSCESSES , may spread caudally to present as a perianal abscess, laterally across the external sphincter to form an ischiorectal abscess or, rarely, superiorly above the anorectal junction
More informationThe role of biologics in pelvic floor surgery
Review article doi:10.1111/codi.12045 The role of biologics in pelvic floor surgery M. Ahmad*, P. Sileri, L. Franceschilli and M. Mercer-Jones* *Department of Colorectal Surgery, Queen Elizabeth Hospital,
More informationNovel Options for the Management of Fecal Incontinence
Novel Options for the Management of Fecal Incontinence Arnold Wald, MD, MACG University of Wisconsin School of Medicine and Public Health, Madison WI ANORECTAL CONTINENCE MECHANISMS Reservoir Elements
More informationAn Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence
European Urology European Urology 48 (2005) 488 494 Female UrologyöIncontinence An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence Christopher R. Chapple
More informationAccidental Bowel Leakage (Fecal Incontinence)
Accidental Bowel Leakage (Fecal Incontinence) What is Accidental Bowel Leakage (ABL)? Accidental bowel leakage is the inability to control solid or liquid stool. This is the inability to control gas and
More informationSACRAL NERVE STIMULATION FOR EXPERIENCE IN CHILDREN
SACRAL NERVE STIMULATION FOR COLORECTAL DISEASES: EXPERIENCE IN CHILDREN C. LOUIS-BORRIONE - JM. GUYS TIMONE-ENFANTS MARSEILLE SACRAL NEUROMODULATION IN CHILDREN 26 : Humphreys et al - 23 children with
More informationColoproctology Section, Department of Surgery, Virgen del Rocio University Hospital, Avenida Manuel Siurot s/n,
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2010, Article ID 467136, 10 pages doi:10.1155/2010/467136 Research Article An Open-Label, Noncomparative, Multicenter Study
More informationCurrent Perspectives in Fecal Incontinence Treatment: The Use of Devices for the Management of Fecal Incontinence-An Evidence-Based Discussion
Current Perspectives in Fecal Incontinence Treatment: The Use of Devices for the Management of Fecal Incontinence-An Evidence-Based Discussion Holly E. Richter, PhD, MD, FACOG, FACS J Marion Sims Professor
More informationReferral for anorectal function evaluation is indicated in 65% and beneficial in 92% of patients
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 January 14; 14(2): 272-277 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2008 WJG. All rights reserved. RAPID COMMUNICATION
More informationOptimising the outcome of neuromodulation for faecal incontinence and constipation. Mr Gregory Paul Thomas. Imperial College. London, United Kingdom
Optimising the outcome of neuromodulation for faecal incontinence and constipation Mr Gregory Paul Thomas Imperial College London, United Kingdom Department of Surgery and Cancer MD (Res) 1 Declaration
More informationRadiologic Features of Implants After Endoscopic Treatment of Vesicoureteral Reflux in Children
Pediatric Imaging Pictorial Essay Cerwinka et al. Implants After Endoscopic Treatment of VUR Pediatric Imaging Pictorial Essay Wolfgang H. Cerwinka 1 Jonathan D. Kaye 1 Hal C. Scherz 1 Andrew J. Kirsch
More informationProtocol. Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux
Protocol Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (701102) Medical Benefit Effective Date: 10/01/14 Next Review Date: 11/19 Preauthorization No Review Dates: 09/10, 09/11, 09/12,
More informationCorporate Medical Policy
Corporate Medical Policy Sacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction File Name: Origination: Last CAP Review: Next CAP Review: Last Review: sacral_nerve_neuromodulation_stimulation_for_pelvic_floor_dysfunction
More informationProtocol. Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux
Protocol Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (701102) Medical Benefit Effective Date: 10/01/14 Next Review Date: 11/18 Preauthorization Yes Review Dates: 09/10, 09/11, 09/12,
More informationEPISIOTOMY & PERINEAL TEARS Anatomy &Functionality May Dr. Annie Leong MBBS, FRANZCOG, CU
EPISIOTOMY & PERINEAL TEARS Anatomy &Functionality May 2011 Dr. Annie Leong MBBS, FRANZCOG, CU Restore normal perineal anatomy Achieve good haemostasis Avoid infection and wound breakdown Avoid coital
More informationHaemorrhoidal disorders -What is the optimal treatment?
Haemorrhoidal disorders -What is the optimal treatment? Per-Olof Nyström, M.D., Ph.D. Professor of Surgery Karolinska Institutet and Karolinska University Hospital Huddinge Stockholm, Sweden The methods
More informationUrogynecology: Evidence-Based Clinical Practice
Urogynecology: Evidence-Based Clinical Practice Kate H. Moore Urogynecology: Evidence-Based Clinical Practice Second Edition Kate H. Moore, MBBS, FRCOG, FRANZCOG, MD, CU Department Obstetrics & Gynaecology
More informationPERMACOL TM COLLAGEN PASTE FOR ANAL FISTULA TREATMENT EXPERT OPINION PRACTICE-BASED RECOMMENDATIONS
PERMACOL TM COLLAGEN PASTE FOR ANAL FISTULA TREATMENT EXPERT OPINION PRACTICE-BASED RECOMMENDATIONS W H I T E PA P E R This whitepaper is the result of the expert consensus meeting on anal fistula treatment
More informationAnal Sphincter Injuries: Acute Management
Anal Sphincter Injuries: Acute Management Dr Stephen Jeffery Urogynaecology Consultant Department of Obstetrics & Gynaecology Groote Schuur Hospital Colorectal Surgeons Gynaecologists Gynaecologists Colorectal
More informationACCIDENTAL BOWEL LEAKAGE: A PRACTICAL APPROACH TO EVALUATION. Tristi W. Muir, MD Chair, Department of OB/GYN Houston Methodist Hospital
ACCIDENTAL BOWEL LEAKAGE: A PRACTICAL APPROACH TO EVALUATION Tristi W. Muir, MD Chair, Department of OB/GYN Houston Methodist Hospital Accidental Bowel Leakage What Gets the Woman into Your Office 67%
More informationCorporate Medical Policy Gastroesophageal Reflux Disease, Transendoscopic Therapies
Corporate Medical Policy Gastroesophageal Reflux Disease, Transendoscopic Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gastroesophageal_reflux_disease_transendoscopic_therapies
More informationPARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS. A08/S/d Colorectal: Faecal Incontinence (Adult)
A08/S/d 2013/14 NHS STANDARD CONTRACT FOR COLORECTAL: FAECAL INCONTINENCE (ADULT) PARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS Service Specification No. Service Commissioner Lead Provider
More informationA70.4 Insertion of neurostimulator electrodes into peripheral nerve Z12.2 Posterior tibial nerve R15.X Faecal incontinence
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous tibial nerve stimulation (PTNS) for
More informationTel Aviv Sourasky Medical Center
Yehuda Kariv, MD Colorectal Unit Division of Surgery Tel Aviv Sourasky Medical Center Basic concepts Current evidence What s new Proposed treatment algorithm Mechanism of Disease Internal sphincter hypertonicity
More informationUse of gatekeeper in obese patients with fecal incontinence before bariatric surgery, is it improving the results?
International Surgery Journal Ibrahim AAM. Int Surg J. 2017 Nov;4(11):3594-3598 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20174876
More informationfrom Bowel Control Problems twitter.com/voicesforpfd
BREAK FREE from Bowel Control Problems POP Quiz THE NUMBER OF PEOPLE IN THE UNITED STATES WITH BOWEL CONTROL PROBLEMS: A. 6 million B. 12 million C. 18 million BOWEL CONTROL PROBLEMS Nearly 18 million
More informationHemorrhoids. Carlos R. Alvarez-Allende PGY-III Colorectal Surgery
Hemorrhoids Carlos R. Alvarez-Allende PGY-III Colorectal Surgery Overview Anatomy Classification Etiology Incidence Symptoms Differential Diagnosis Medical Management Surgical Management Anatomy Anal canal
More informationFunctional anorectal disorders
Functional anorectal disorders Anton Emmanuel Swiss Coloproctology Study Group, January 2019 National Hospital for Neurology & Neurosurgery Approach Pelvic floor neurophysiology Faecal incontinence (Dr
More informationRectal irrigation: a useful tool in the armamentarium for functional bowel disorders
Original article doi:10.1111/j.1463-1318.2011.02797.x Rectal irrigation: a useful tool in the armamentarium for functional bowel disorders D. S. Y. Chan*, A. Saklani, P. R. Shah, M. Lewis and P. N. Haray
More informationDOWNLOAD OR READ : URINARY FECAL INCONTINENCE CURRENT MANAGEMENT CONCEPTS URINARY AND FECAL INCONTINENCE PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : URINARY FECAL INCONTINENCE CURRENT MANAGEMENT CONCEPTS URINARY AND FECAL INCONTINENCE PDF EBOOK EPUB MOBI Page 1 Page 2 urinary fecal incontinence current pdf Discusses urinary incontinence
More informationTertiary, regional and local pelvic floor service providers: the future. model? Andrew Williams
Tertiary, regional and local pelvic floor service providers: the future Andrew Williams model? Pelvic Floor Unit Guy s and St Thomas NHS Foundation Trust Background 23% women suffer at least one pelvic
More informationStrategies for Anorectal Disorders
Strategies for Anorectal Disorders Professor of Medicine Director of Gastrointestinal Endoscopy Temple University School of Medicine Disclosure of Conflicts of Interest I have no affiliations with commercial
More informationDescription. Section: Surgery Effective Date: April 15, Subsection: Surgery Original Policy Date: December 6, 2012 Subject:
Last Review Status/Date: March 2015 Page: 1 of 11 Description Vesicoureteral reflux (VUR) is the retrograde flow of urine from the bladder upward toward the kidney and is most commonly seen in children.
More informationLONG TERM OUTCOME OF ELECTIVE SURGERY
LONG TERM OUTCOME OF ELECTIVE SURGERY Roberto Persiani Associate Professor Mini-invasive Oncological Surgery Unit Institute of Surgical Pathology (Dir. prof. D. D Ugo) Dis Colon Rectum, March 2000 Dis
More informationPerineale Rektumprolapsoperation: Gute Resultate bei geringem Aufwand! F.H. Hetzer
Perineale Rektumprolapsoperation: Gute Resultate bei geringem Aufwand! F.H. Hetzer STARR: Wunderwaffe beim Obstructed Defecation Syndrom (ODS) F.H. Hetzer Stapled TransAnal Rectal Resection STARR PPH 01
More informationSacral Nerve Neuromodulation/Stimulation
Protocol Sacral Nerve Neuromodulation/Stimulation (70169) Medical Benefit Effective Date: 01/01/14 Next Review Date: 09/14 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11, 09/12, 09/13
More information